talazoparib,atezolizumab
pfizer,roche
['atezo', 'congrat', 'talazo', 'biomarker', 'lung', 'sclc']
#asco23 lung orals s1929 trial atezo v atezo+talazoparib in es sclc shows pfs benefit (hr 0.7, p=0.05) for combo in slfn11+ sclc. slfn-11 ihc done completed in &gt;80%pts a biomarker-informed approach in sclc? this is massive congrats 
Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University